Compare Amphastar Pharmaceuticals Inc (AMPH) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Yum! Brands, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Yum! Brands, Inc. trades at $145.4 (market cap $39.66B). The key difference: Yum! Brands, Inc. is far larger — about 45.9× Amphastar Pharmaceuticals Inc's market cap, and Yum! Brands, Inc. pays a 2.06% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | YUM | |
|---|---|---|
Market Cap | $863.95M | $39.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $168.16 |
52-Week Low | $16.87 | $138.21 |
Enterprise Value | $1.26B | $51.26B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
YUM trades at $150.76, down 0.95% on the day, amid a bearish technical signal and recent sales headwinds from a parasite outbreak affecting Taco Bell. The company reported Q2 2026 EPS of $1.62, beating estimates, and completed the $1.2 billion sale of Pizza Hut China. Revenue growth is steady, with 2025 revenue at $8.21 billion and net income margin of 25.4%, though debt remains elevated. Analyst consensus is a Buy with a $174.60 price target, but legal investigations and food safety concerns present near-term risks.
The outlook is mixed: strong digital growth and portfolio streamlining offer upside, but the stock faces pressure from the cyclospora outbreak's impact on sales and ongoing fraud probes. Investors should weigh solid fundamentals against sentiment-driven volatility and high leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
